Stocks of Smith & Nephew plc (NYSE:SNN) traded higher last session on Wall Street, down -1.05% to $28.30.
As we calculate the median target price by taking the range between a high of $36.57 and a low of $23.18, we find $30.95. Given the previous closing price of $28.60, this indicates a potential upside of 8.22 percent. SNN stock price is now 7.65% away from the 50-day moving average and 3.31% away from the 200-day moving average. The market capitalization of the company currently stands at $11.99B.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our
5 Best Growth Stocks To Own For 2023.
Sponsored
Brokers who have rated the stock have averaged $30.62 as their price target over the next twelve months.
, while ‘Morgan Stanley’ rates the stock as ‘Equal-Weight’.
A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in SNN stock. A new stake in Smith & Nephew plc shares was purchased by SCHARF INVESTMENTS, LLC during the first quarter worth $58,495,000. POINT72 ASSET MANAGEMENT, L.P. invested $12,595,000 in shares of SNN during the first quarter. In the first quarter, RUSSELL INVESTMENTS GROUP, LTD. acquired a new stake in Smith & Nephew plc valued at approximately $6,615,000. SIO CAPITAL MANAGEMENT, LLC acquired a new stake in SNN for approximately $6,463,000. TWIN TREE MANAGEMENT, LP purchased a new stake in SNN valued at around $6,452,000 in the second quarter. In total, there are 249 active investors with 9.80% ownership of the company’s stock.
Thursday’s opening bell rang with an opening price of $28.58 for Smith & Nephew plc (NYSE: SNN). During the past 12 months, Smith & Nephew plc has had a low of $21.77 and a high of $36.14. As of last week, the company has a debt-to-equity ratio of 0.54, a current ratio of 1.80, and a quick ratio of 0.80. The fifty day moving average price for SNN is $26.37 and a two-hundred day moving average price translates $27.37 for the stock.
The latest earnings results from Smith & Nephew plc (NYSE: SNN) was released for Jul, 2022. The net profit margin was 9.50% and return on equity was 9.20% for SNN.
Moreover, the firm recently paid out its quarterly dividend on 05/11/2022. Investors who held shares on 04/01/2022 were paid a $0.462 dividend. On an annualized basis, this represents a $1.04 dividend and a 3.67% percent yield. There was an ex-dividend date of 03/31/2022 for this dividend.
Smith & Nephew plc(SNN) Company Profile
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.
